BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

BioTech Health X

803 posts
Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial

Biotech NewsKrystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial

  • BioTech Health X
  • August 1, 2022
Leader in redosable gene therapy Krystal Biotech, Inc. (NASDAQ: KRYS) announced today the United States Food and Drug…
0 Shares
0
0
0
0
0
0
0
ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug

Biotech NewsImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug

  • BioTech Health X
  • July 28, 2022
In breaking news, clinical-stage biotechnology company ImmunityBio, Inc. (NASDAQ: IBRX) has announced acceptance by the FDA review of…
0 Shares
0
0
0
0
0
0
0
Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement

Biotech NewsBrickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement

  • BioTech Health X
  • July 20, 2022
Clinical-stage pharmaceutical company Brickell Biotech, Inc. (Nasdaq: BBI) announced that the company has received formal notice from The…
0 Shares
0
0
0
0
0
0
0
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

  • BioTech Health X
  • July 20, 2022
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
0 Shares
0
0
0
0
0
0
0

Biotech InfoWhat is Biotechnology: Types, Examples and Applications

  • BioTech Health X
  • June 24, 2022
Understanding biotechnology Biotech involves studying organism functions at the molecular level and is often combined with many different…
0 Shares
0
0
0
0
0
0
0
Ocugen Announces FDA Clinical Hold Removal for Phase 2:3 COVAXIN BBV152 Clinical Trial

Biotech NewsOcugen Announces FDA Clinical Hold Removal for Phase 2/3 COVAXIN (BBV152) Clinical Trial

  • BioTech Health X
  • May 23, 2022
Biotechnology company Ocugen, Inc. (NASDAQ: OCGN) announced today that the U.S. Food and Drug Administration (FDA) has removed…
0 Shares
0
0
0
0
0
0
0
BenchSci Expands Advisory Board with New Pharma R&D Leaders

Biotech NewsBenchSci Expands Advisory Board with New Pharma R&D Leaders

  • BioTech Health X
  • April 21, 2022
BenchSci has welcomed three new members to its advisory board from the pharmacology sector. Steve Hitchcock of Takeda…
0 Shares
0
0
0
0
0
0
0
EF Hutton Initiates Coverage of Cel-Sci CVM with 17 Price Target Ahead of Rumored News

Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News

  • BioTech Health X
  • April 7, 2022
Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
0 Shares
0
0
0
0
0
0
0
Legend Biotech Appoints Dr Guowei Fang Head of Global Research and Early Development

Biotech NewsLegend Biotech Appoints Dr. Guowei Fang As Head of Global Research and Early Development

  • BioTech Health X
  • April 1, 2022
Global biotechnology company Legend Biotech Corporation (NASDAQ: LEGN) announced today that Guowei Fang, Ph.D. will take over as…
0 Shares
0
0
0
0
0
0
0
2seventy-bio-Secure-170-Million-Extending-Cash-Runway-Into-2025

Biotech News2seventy bio Secure $170 Million Extending Cash Runway Into 2025

  • BioTech Health X
  • March 16, 2022
2seventy bio (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that it has agreed to sell…
0 Shares
0
0
0
0
0
0
0
Inhibikase-Therapeutics-Present-Phase-1-1b-Trial-Results-ADPD-Alzheimers-Parkinsons-Diseases-Conference

Biotech NewsInhibikase Therapeutics To Present Phase 1/1b Trial Results at AD/PD Alzheimer’s & Parkinson’s Diseases Conference

  • BioTech Health X
  • March 8, 2022
Clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. (Nasdaq: IKT) recently announced that President and CEO Dr. Milton Werner, Ph.D. will be…
0 Shares
0
0
0
0
0
0
0
Celyad-Oncology-Pauses-CYAD-101-002-Keynote-B79-Phase-1-Trial-After-2-Deaths-Reported

Biotech NewsCelyad Oncology Pauses CYAD-101-002 (Keynote-B79) Phase 1 Trial After 2 Deaths Reported

  • BioTech Health X
  • February 28, 2022
Clinical-stage biotechnology company Celyad Oncology (NASDAQ: CYAD) recently announced that the company has voluntarily paused the CYAD-101-002 (KEYNOTE-B79)…
0 Shares
0
0
0
0
0
0
0
Cellarity-Expands-Leadership-Team-to-Continue-Evolution-of-Breakthrough-Platform-to-Encode-Biology-and-Purposefully-Create-New-DrugsCellarity-Expands-Leadership-Team

Biotech NewsCellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs

  • BioTech Health X
  • February 10, 2022
With the appointments of these experts, the firm has added to its industry knowledge, including Chief Scientific Officer…
0 Shares
0
0
0
0
0
0
0
BioTech Health X CEO Series Virios Therapeutics Greg Duncan

BioTech CEO InterviewsBioTech Health X CEO Series: Virios Therapeutics Greg Duncan

  • BioTech Health X
  • February 1, 2022
BioTech Health X works to deliver the latest coverage and updates in the biotechnology sector. This includes providing…
0 Shares
0
0
0
0
0
0
0
Nasdaq Biotechnology Index Adds Quantum-Si Nasdaq QSI Life Sciences Company

Biotech NewsNasdaq Biotechnology Index Adds Quantum-Si (Nasdaq: QSI) Life Sciences Company

  • BioTech Health X
  • December 14, 2021
Quantum-Si (Nasdaq: QSI), a life science instrumentation firm commercializing a distinctive protein sequencing technology, has been added to…
0 Shares
0
0
0
0
0
0
0
Sigilon Therapeutics Provides Update on Strategic Reprioritization

Biotech NewsSigilon Therapeutics Provides Update on Strategic Reprioritization

  • BioTech Health X
  • December 13, 2021
San Francisco, California-based biotechnology firm Sigilon Therapeutics, Inc. (NASDAQ: SGTX) has announced a strategic re-prioritization to enable the…
0 Shares
0
0
0
0
0
0
0
What is the difference between Biotech versus Medtech

Biotech NewsWhat is the Difference Between Biotech versus Medtech?

  • BioTech Health X
  • November 25, 2021
0 Shares
0
0
0
0
0
0
0
Ortho Clinical Diagnostics Overview & Q&A

BioTech CEO InterviewsOrtho Clinical Diagnostics Overview & Q&A Interview

  • BioTech Health X
  • November 19, 2021
Michael S. Iskra, Executive Vice President of Commercial Excellence and Strategy at Ortho Clinical Diagnostics  I’d be happy…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • PMV Pharmaceuticals (PMVP) Forecast 2026: One Mutation, One Oral Drug, and a Re-Rating That Could Hit Fast
  • Oncolytics (ONCY) Is a $90M “Science vs. Reality” Fight—And 2026 Is When Pelareorep Has to Win
  • Nkarta (NKTX)’s Plot Twist: From Cancer Chaos to Autoimmune “Immune Reset” Hype
  • Context (CNTX)’s Glow-Up: From “Old Thesis” to T-Cell Engager Chaos (In a Good Way)
  • The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • February 13, 2026
    PMV Pharmaceuticals (PMVP) Forecast 2026: One Mutation, One Oral Drug, and a Re-Rating That Could Hit Fast
    • February 13, 2026
    Oncolytics (ONCY) Is a $90M “Science vs. Reality” Fight—And 2026 Is When Pelareorep Has to Win
    • February 13, 2026
    Nkarta (NKTX)’s Plot Twist: From Cancer Chaos to Autoimmune “Immune Reset” Hype
    • February 13, 2026
    Context (CNTX)’s Glow-Up: From “Old Thesis” to T-Cell Engager Chaos (In a Good Way)
    • February 13, 2026
    The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
Recent Posts
  • Verastem (VSTM) Isn’t “Small-Cap Roulette” Anymore—It’s a Commercial Oncology Ramp With a 2026 Twist
    • February 13, 2026
  • The Market Cap Is Small, the Idea Is Huge: Can Allogene (ALLO) Make CAR-T as Easy as Ordering a Drug?
    • February 13, 2026
  • 44% Real-World Response? Iovance (IOVA) Just Made “Off-the-Bench” Data the New Headline
    • February 13, 2026
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (5)
  • Biotech News (787)
  • Uncategorized (2)
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top